Literature DB >> 18825472

Variables related to utility in patients with ankylosing spondylitis.

Rafael Ariza-Ariza1, Blanca Hernández-Cruz, Gloria López-Antequera, Federico Navarro-Sarabia.   

Abstract

The objective of this study was to identify variables associated to the utility of the health states in patients with ankylosing spondylitis (AS). A cross-sectional study was performed in a tertiary care centre. AS patients (New York modified criteria) were included. Demographic and disease-related variables were collected. The social tariffs of the EuroQol-5D (EQ-5D) were used to obtain utility values. Univariate and multivariate regression analyses were used in order to identify variables associated with utility. Seventy patients, 52 male (74.3%), with age (mean +/- SD) 43.7 +/- 9.1 years and disease duration 10.8 +/- 8.1 years, were included. The mean utility was 0.5625 +/- 0.3364. In the univariate analysis, patient global assessment, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) had a good correlation with the EQ-5D values (Pearson's product moment correlation coefficient r > 0.6) whereas physician global assessment, patient pain assessment, and cervical rotation had a moderate correlation with the EQ-5D (0.6 > r > 0.4). Patients with significant comorbidity had lower utility values (0.3563 +/- 0.068) than those without it (0.6796 +/- 0.041, p = 0.0001). In the multivariate analysis, BASFI and BASDAI kept an independent association with utility and they explained a 62% of the variance of the utility values. In this study, physical function and disease activity, two outcomes with good responsiveness to the treatment, were the main determinants of the utility of the health states in AS patients.

Entities:  

Mesh:

Year:  2008        PMID: 18825472     DOI: 10.1007/s10067-008-1019-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

1.  Development and testing of the UK SF-12 (short form health survey).

Authors:  C Jenkinson; R Layte
Journal:  J Health Serv Res Policy       Date:  1997-01

2.  How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?

Authors:  Annelies Boonen; Désirée van der Heijde; Robert Landewé; Astrid van Tubergen; Herman Mielants; Maxime Dougados; Sjef van der Linden
Journal:  Ann Rheum Dis       Date:  2007-01-09       Impact factor: 19.103

3.  Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis.

Authors:  S M M Verstappen; J W G Jacobs; D M van der Heijde; Sj van der Linden; C M Verhoef; J W J Bijlsma; A Boonen
Journal:  Ann Rheum Dis       Date:  2006-12-15       Impact factor: 19.103

Review 4.  Utility approach to measuring health-related quality of life.

Authors:  G W Torrance
Journal:  J Chronic Dis       Date:  1987

5.  Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients.

Authors:  Ahmet Ozgül; Fatma Peker; M Ali Taskaynatan; A Kenan Tan; Kemal Dinçer; Tunç Alp Kalyon
Journal:  Clin Rheumatol       Date:  2005-08-10       Impact factor: 2.980

6.  Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis.

Authors:  Rafael Ariza-Ariza; Blanca Hernández-Cruz; Federico Navarro-Sarabia
Journal:  Arthritis Rheum       Date:  2003-08-15

7.  Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.

Authors:  Annelies Boonen; Vaishali Patel; Shana Traina; Chiun-Fang Chiou; Andreas Maetzel; Wayne Tsuji
Journal:  J Rheumatol       Date:  2008-02-15       Impact factor: 4.666

8.  Costs and quality of life of patients with ankylosing spondylitis in Canada.

Authors:  Gisela Kobelt; Patrik Andlin-Sobocki; Walter P Maksymowych
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

9.  Methodological issues of patient utility measurement. Experience from two clinical trials.

Authors:  M P Rutten-van Mölken; C H Bakker; E K van Doorslaer; S van der Linden
Journal:  Med Care       Date:  1995-09       Impact factor: 2.983

10.  Health related utility measurement: an introduction.

Authors:  C Bakker; S van der Linden
Journal:  J Rheumatol       Date:  1995-06       Impact factor: 4.666

View more
  6 in total

1.  Associations between illness duration and health-related quality of life in specified mental and physical chronic health conditions: results from a population-based survey.

Authors:  Lucy Busija; Jeretine Tan; Kerrie M Sanders
Journal:  Qual Life Res       Date:  2017-05-12       Impact factor: 4.147

2.  Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis.

Authors:  U Kiltz; D L Keininger; E A Holdsworth; N Booth; O Howell; N Modi; H Tian; P G Conaghan
Journal:  Clin Rheumatol       Date:  2021-11-20       Impact factor: 2.980

Review 3.  Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature.

Authors:  Juan Carlos Torre-Alonso; Rubén Queiro; Marta Comellas; Luís Lizán; Carles Blanch
Journal:  Patient Prefer Adherence       Date:  2018-05-08       Impact factor: 2.711

4.  Research hotspots and trends analysis of ankylosing spondylitis: a bibliometric and scientometric analysis from 2009 to 2018.

Authors:  Miaomiao Liang; Yan Meng; Siming Zhou; Zhengbo Tao; Lin Tao
Journal:  Ann Transl Med       Date:  2020-11

5.  Biologic use in psoriatic arthritis and ankylosing spondylitis patients: a descriptive epidemiological study using linked, routine data in Wales, UK.

Authors:  Roxanne Cooksey; Muhammad Azizur Rahman; Jonathan Kennedy; Sinead Brophy; Ernest Choy
Journal:  Rheumatol Adv Pract       Date:  2021-06-27

6.  Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.

Authors:  Sizheng Steven Zhao; Selina Robertson; Tzvi Reich; Nicolas L Harrison; Robert J Moots; Nicola J Goodson
Journal:  Rheumatology (Oxford)       Date:  2020-10-01       Impact factor: 7.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.